Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/30/2022 | 60.82% | Morgan Stanley | $75 → $71 | Maintains | Equal-Weight |
09/07/2022 | 72.14% | Mizuho | → $76 | Assumes | → Buy |
08/30/2022 | 69.88% | Morgan Stanley | $55 → $75 | Maintains | Equal-Weight |
08/23/2022 | 375.65% | HC Wainwright & Co. | $180 → $210 | Maintains | Buy |
08/22/2022 | 69.88% | SVB Leerink | $50 → $75 | Maintains | Outperform |
08/10/2022 | 24.58% | Morgan Stanley | $54 → $55 | Maintains | Equal-Weight |
07/08/2022 | 22.31% | Morgan Stanley | $27 → $54 | Maintains | Equal-Weight |
06/29/2022 | 194.45% | Cowen & Co. | $120 → $130 | Maintains | Outperform |
06/29/2022 | 44.96% | Cantor Fitzgerald | $47 → $64 | Maintains | Overweight |
05/03/2022 | 10.99% | Mizuho | $51 → $49 | Maintains | Buy |
04/27/2022 | -38.84% | Morgan Stanley | $34 → $27 | Maintains | Equal-Weight |
03/29/2022 | 74.41% | Jefferies | $71 → $77 | Maintains | Buy |
03/02/2022 | 13.25% | SVB Leerink | $65 → $50 | Maintains | Outperform |
11/09/2021 | 47.23% | SVB Leerink | $75 → $65 | Maintains | Outperform |
08/30/2021 | 307.7% | HC Wainwright & Co. | $225 → $180 | Maintains | Buy |
08/10/2021 | 69.88% | SVB Leerink | $115 → $75 | Maintains | Outperform |
08/10/2021 | 262.4% | Truist Securities | $200 → $160 | Maintains | Buy |
08/10/2021 | 24.58% | Mizuho | $118 → $55 | Maintains | Buy |
08/10/2021 | -22.99% | Morgan Stanley | $105 → $34 | Downgrades | Overweight → Equal-Weight |
06/10/2021 | 153.68% | Berenberg | → $112 | Initiates Coverage On | → Buy |
05/26/2021 | 137.83% | Morgan Stanley | $104 → $105 | Maintains | Overweight |
04/27/2021 | 409.63% | HC Wainwright & Co. | $210 → $225 | Maintains | Buy |
03/02/2021 | 135.56% | Morgan Stanley | $101 → $104 | Maintains | Overweight |
01/08/2021 | 192.19% | Jefferies | → $129 | Initiates Coverage On | → Buy |
12/16/2020 | 171.8% | Mizuho | → $120 | Initiates Coverage On | → Buy |
11/09/2020 | 128.77% | Morgan Stanley | $102 → $101 | Maintains | Overweight |
09/29/2020 | 49.49% | B of A Securities | → $66 | Initiates Coverage On | → Underperform |
09/10/2020 | 131.03% | Morgan Stanley | → $102 | Initiates Coverage On | → Overweight |
04/28/2020 | 375.65% | HC Wainwright & Co. | $200 → $210 | Maintains | Buy |
04/28/2020 | 196.72% | Cantor Fitzgerald | $125 → $131 | Maintains | Overweight |
04/14/2020 | 115.18% | Cowen & Co. | → $95 | Initiates Coverage On | → Outperform |
12/30/2019 | 183.13% | Cantor Fitzgerald | $104 → $125 | Reiterates | → Overweight |
12/30/2019 | 353% | HC Wainwright & Co. | $170 → $200 | Maintains | Buy |
12/16/2019 | 257.87% | Guggenheim | $65 → $158 | Maintains | Buy |
12/16/2019 | 135.56% | Cantor Fitzgerald | $55 → $104 | Maintains | Overweight |
10/16/2019 | 8.72% | Guggenheim | → $48 | Initiates Coverage On | → Buy |
09/18/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
04/08/2019 | -43.37% | SVB Leerink | → $25 | Initiates Coverage On | → Outperform |
03/21/2019 | -43.37% | Cantor Fitzgerald | $16 → $25 | Maintains | Overweight |
11/15/2018 | -63.76% | Cantor Fitzgerald | → $16 | Reinstates | → Overweight |
06/07/2018 | -77.35% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
Axsome Therapeutics Questions & Answers
The latest price target for Axsome Therapeutics (NASDAQ: AXSM) was reported by Morgan Stanley on September 30, 2022. The analyst firm set a price target for $71.00 expecting AXSM to rise to within 12 months (a possible 60.82% upside). 14 analyst firms have reported ratings in the last year.
The latest analyst rating for Axsome Therapeutics (NASDAQ: AXSM) was provided by Morgan Stanley, and Axsome Therapeutics maintained their equal-weight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axsome Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axsome Therapeutics was filed on September 30, 2022 so you should expect the next rating to be made available sometime around September 30, 2023.
While ratings are subjective and will change, the latest Axsome Therapeutics (AXSM) rating was a maintained with a price target of $75.00 to $71.00. The current price Axsome Therapeutics (AXSM) is trading at is $44.15, which is out of the analyst's predicted range.